Tara Maria DeSilva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tara Maria DeSilva has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Gabrielle M. Mey
7 shared publicationsJohn Shelestak
5 shared publicationsMuhammad Irfan
5 shared publicationsMcKenzie K. Chappell
4 shared publicationsAshley D. Nemes-Baran
3 shared publicationsKirsten S. Evonuk
Department of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA
3 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by Elsevier in STAR Protocols
- Vol. 6 (2) , 103860
Protocol for assessing regional pathology in the rodent optic nerve using longitudinal cryosections and cross-sectional electron microscopy
- 4 June 2025
- Published by Elsevier in STAR Protocols
- Vol. 6 (2) , 103860
Open AccessProtocol for assessing regional pathology in the rodent optic nerve using longitudinal cryosections and cross-sectional electron microscopy
- Open Access
- 20 February 2025
- Published by Elsevier in Neuroscience
- Vol. 570, 159-172
Morphological and functional differences between hippocampal and cortical microglia and its impact on neuronal over-excitation in a germline Pten mutant mouse model
- 20 February 2025
- Published by Elsevier in Neuroscience
- Vol. 570, 159-172
Open AccessMorphological and functional differences between hippocampal and cortical microglia and its impact on neuronal over-excitation in a germline Pten mutant mouse model
- Open Access
Cerebellar white matter development is regulated by fractalkine-dependent microglia phagocytosis of oligodendrocyte progenitor cells
Summary: Complex neurodevelopmental disorders involve motor as well as cognitive dysfunction and these impairments are associated with both cerebral and cerebellar maturity. A network of connections between these two brain regions is proposed to underlie neurodevelopmental impairments. The cerebellar gray matter has a protracted developmental timeline compared to the cerebral cortex, however, making the association of these relay pathways unclear for neurodevelopmental disabilities. We show that a population of amoeboid microglia infiltrate the cerebellar white matter through the fourth ventricular zone during early postnatal development. This infiltration is synchronized with the emergence of amoeboid microglia in the ventricular zone of the lateral ventricles and appearance in cerebral white matter. Amoeboid microglia phagocytosed oligodendrocyte progenitor cells (OPCs) in the cerebellar white matter during a restricted early postnatal time window before transitioning to a ramified morphology. Modulating fractalkine receptor signaling, shown to be involved in microglial pruning of synapses, significantly reduced microglial engulfment of OPCs resulting in increased numbers of OLs and altered myelin formation. Variants in the fractalkine receptor are associated with neurodevelopmental disorders including schizophrenia and autism where myelin perturbations have been documented. Overall, these data support that white matter refinement by amoeboid microglia is coordinated in both cerebral and cerebellar development with important implications for altered circuit function in neurodevelopmental disabilities. One sentence summary: Microglia engulf oligodendrocyte progenitors in the developing cerebellum
Open AccessCerebellar white matter development is regulated by fractalkine-dependent microglia phagocytosis of oligodendrocyte progenitor cells
Summary: Complex neurodevelopmental disorders involve motor as well as cognitive dysfunction and these impairments are associated with both cerebral and cerebellar maturity. A network of connections between these two brain regions is proposed to underlie neurodevelopmental impairments. The cerebellar gray matter has a protracted developmental timeline compared to the cerebral cortex, however, making the association of these relay pathways unclear for neurodevelopmental disabilities. We show that a population of amoeboid microglia infiltrate the cerebellar white matter through the fourth ventricular zone during early postnatal development. This infiltration is synchronized with the emergence of amoeboid microglia in the ventricular zone of the lateral ventricles and appearance in cerebral white matter. Amoeboid microglia phagocytosed oligodendrocyte progenitor cells (OPCs) in the cerebellar white matter during a restricted early postnatal time window before transitioning to a ramified morphology. Modulating fractalkine receptor signaling, shown to be involved in microglial pruning of synapses, significantly reduced microglial engulfment of OPCs resulting in increased numbers of OLs and altered myelin formation. Variants in the fractalkine receptor are associated with neurodevelopmental disorders including schizophrenia and autism where myelin perturbations have been documented. Overall, these data support that white matter refinement by amoeboid microglia is coordinated in both cerebral and cerebellar development with important implications for altered circuit function in neurodevelopmental disabilities. One sentence summary: Microglia engulf oligodendrocyte progenitors in the developing cerebellum
- Open Access
- 1 January 2024
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 41 (1) , 140-141
What is the link between white matter lesions and neurodegeneration?
Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, examines the link between white matter lesions and neurodegeneration
- 1 January 2024
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 41 (1) , 140-141
Open AccessWhat is the link between white matter lesions and neurodegeneration?
Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, examines the link between white matter lesions and neurodegeneration
- Open Access
- 13 June 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1229625
Editorial: Animal models of multiple sclerosis: can they advance future therapies?
Editorial: Animal models of multiple sclerosis: can they advance future therapies?
- 13 June 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1229625
Open AccessEditorial: Animal models of multiple sclerosis: can they advance future therapies?
Editorial: Animal models of multiple sclerosis: can they advance future therapies?
- Open Access
- 29 March 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1125115
Utility of the visual system to monitor neurodegeneration in multiple sclerosis
Neurodegeneration occurs early in the multiple sclerosis (MS) disease course and is an important driver of permanent disability. Current immunomodulatory therapies do not directly target neuronal health; thus, there is a critical need to develop neuroprotective strategies in MS. Outcome measures in clinical trials primarily evaluate disease activity and clinical disability scores rather than measures of neurodegeneration. The visual system provides a noninvasive correlate of brain atrophy and neuronal function through structural and functional exams. Furthermore, optic nerve axons and their respective neuronal cell bodies in the retina, in addition to their synaptic input to the thalamus, provide a distinct anatomy to investigate neurodegenerative processes. This review discusses the utility of the visual system as an early output measure of neurodegeneration in MS as well as an important platform to evaluate neuroprotective strategies in preclinical models.
- 29 March 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1125115
Open AccessUtility of the visual system to monitor neurodegeneration in multiple sclerosis
Neurodegeneration occurs early in the multiple sclerosis (MS) disease course and is an important driver of permanent disability. Current immunomodulatory therapies do not directly target neuronal health; thus, there is a critical need to develop neuroprotective strategies in MS. Outcome measures in clinical trials primarily evaluate disease activity and clinical disability scores rather than measures of neurodegeneration. The visual system provides a noninvasive correlate of brain atrophy and neuronal function through structural and functional exams. Furthermore, optic nerve axons and their respective neuronal cell bodies in the retina, in addition to their synaptic input to the thalamus, provide a distinct anatomy to investigate neurodegenerative processes. This review discusses the utility of the visual system as an early output measure of neurodegeneration in MS as well as an important platform to evaluate neuroprotective strategies in preclinical models.
- Open Access
- 10 January 2023
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 40 (1) , 108-109
Targeting the central nervous system: The future of therapeutic strategies for MS
Tara M. DeSilva, looks at the future of therapeutic strategies for MS, focusing on targeting the central nervous system
- 10 January 2023
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 40 (1) , 108-109
Open AccessTargeting the central nervous system: The future of therapeutic strategies for MS
Tara M. DeSilva, looks at the future of therapeutic strategies for MS, focusing on targeting the central nervous system
- Open Access
- 1 January 2023
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 37 (1) , 136-137
Remyelinating versus neuroprotective therapies for multiple sclerosis
Remyelinating versus neuroprotective therapies for multiple sclerosis: Reducing clinical relapses and improving quality of life is at the heart of MS treatment; here, Tara M. DeSilva explores the benefits of remyelinating versus neuroprotective therapies for tackling MS. Clinical relapses in the demyelinating and neurodegenerative disease multiple sclerosis (MS) are characterised by neurological symptoms resulting from damage to the myelin sheath that surrounds axons. This damage is perpetrated by immune cells that extravasate into the central nervous system (CNS), including the brain, spinal cord, and optic nerves and are a key underlying pathogenesis of lesion formation. Current therapies for MS reduce the infiltration of immune cells, thereby reducing clinical relapses and improving quality of life. However, inflammatory lesions in the CNS can occur even during remission leading to "silent" lesions that damage myelin and axons. This may explain why current immunomodulatory therapies are effective early in the disease course but do not prevent long-term progressive disease. Therefore, strategies are being developed to promote direct protection of the axon and recovery of the myelin sheath. These strategies, in combination with immunomodulatory therapies, may help to prevent long-term disease progression and promote recovery in MS.
- 1 January 2023
- Published by Adjacent Digital Politics Ltd in Open Access Government
- Vol. 37 (1) , 136-137
Open AccessRemyelinating versus neuroprotective therapies for multiple sclerosis
Remyelinating versus neuroprotective therapies for multiple sclerosis: Reducing clinical relapses and improving quality of life is at the heart of MS treatment; here, Tara M. DeSilva explores the benefits of remyelinating versus neuroprotective therapies for tackling MS. Clinical relapses in the demyelinating and neurodegenerative disease multiple sclerosis (MS) are characterised by neurological symptoms resulting from damage to the myelin sheath that surrounds axons. This damage is perpetrated by immune cells that extravasate into the central nervous system (CNS), including the brain, spinal cord, and optic nerves and are a key underlying pathogenesis of lesion formation. Current therapies for MS reduce the infiltration of immune cells, thereby reducing clinical relapses and improving quality of life. However, inflammatory lesions in the CNS can occur even during remission leading to "silent" lesions that damage myelin and axons. This may explain why current immunomodulatory therapies are effective early in the disease course but do not prevent long-term progressive disease. Therefore, strategies are being developed to promote direct protection of the axon and recovery of the myelin sheath. These strategies, in combination with immunomodulatory therapies, may help to prevent long-term disease progression and promote recovery in MS.